Company / Cost of Revenue
AMICUS THERAPEUTICS, INC. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$72.9M
FY2025
5-year range
$34.5M / $72.9M
FY2021-FY2025
Trend
+37.8%
vs FY2024
Sector context
#50 of 85
Health Care
What the data says
At $73M, AMICUS THERAPEUTICS, INC.'s cost of revenue ranks #36 of 85 in the Health Care sector. Increased from $37M to $73M over the past 2 years.
Based on SEC 10-K filings.
$73M in FY2025 with a 5-year CAGR of +18.6%.
Increased from $37M to $73M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +23.6%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
#36 of 85 in Health CareTop 41% of 85This company $72.9M Sector average $2.0B
▼
-96.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, cost of revenue increased 37.8% year-over-year.
- Ranks #50 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $72.9M | +37.8% |
| FY2024 | $52.9M | +41.8% |
| FY2023 | $37.3M | -3.3% |
| FY2022 | $38.6M | +12.0% |
| FY2021 | $34.5M | +11.0% |
| FY2020 | $31.0M | +41.3% |
| FY2019 | $22.0M | +52.5% |
| FY2018 | $14.4M | +131.0% |
| FY2017 | $6.2M | +648.6% |
| FY2016 | $833.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026